Eiger Mountains

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International D-LIVR Study Enrolling - NDA and MAA filings for Progeria & Progeroid Laminopathies planned for Q4 2019 PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Investor Conferences in August
PALO ALTO, Calif. , Aug. 5, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in
View HTML
Toggle Summary Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
- Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , June 17, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the
View HTML
Toggle Summary Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs
PALO ALTO, Calif. , June 10, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach , PhD, RPh as Vice President of Global Regulatory
View HTML
Toggle Summary Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development
PALO ALTO, Calif. , June 5, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA as Vice President of Global Hepatitis
View HTML
Toggle Summary Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer
PALO ALTO, Calif. , May 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Apelian will step down as the Company's Chief Operating Officer
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International "D-LIVR" Study Underway - NDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019 - Strong Balance Sheet with Recent Financing Completed PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
View HTML
Toggle Summary Eiger to Present at ChinaBio® Partnering Forum 2019
PALO ALTO, Calif. , April 30, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will participate and present a
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share.  All of the shares are being sold by Eiger.
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
PALO ALTO, Calif. , April 17, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock.  All of the shares to be sold in the offering are to be sold by Eiger.
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors
PALO ALTO, Calif. , April 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev , JD to its Board of Directors.  Mr.
View HTML
Toggle Summary Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
- Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa - Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif. , April 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and
View HTML
Toggle Summary Eiger BioPharmaceuticals to Participate in Conferences in April
PALO ALTO, Calif. , March 26, 2019 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
- Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia - Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif. , March 25, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted
View HTML
Toggle Summary Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
PALO ALTO, Calif. , March 20, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Began 2019 with $100.4 million in cash, cash equivalents & short-term investments - Enrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019 - NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif. , March 14, 2019 /PRNewswire/ -- Eiger
View HTML
Toggle Summary Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
- 36% Durable Virologic Response at 24 Weeks Post-Treatment PALO ALTO, Calif. , March 13, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced a
View HTML
Toggle Summary Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
PALO ALTO, Calif. , March 11, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory , President and CEO, will present a corporate update at
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
PALO ALTO, Calif. , Feb. 27, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company's General Counsel,
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif. , Feb. 6, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today that the European
View HTML
Toggle Summary Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
PALO ALTO, Calif. , Feb. 4, 2019 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results of the Phase 2 PREVENT study at ENDO 2019 in
View HTML
Toggle Summary Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
PALO ALTO, Calif. , Jan. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray , MS, RAC to its Board of Directors.  Ms.
View HTML